Cancer and Metastasis Reviews

Papers
(The TQCC of Cancer and Metastasis Reviews is 18. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-07-01 to 2025-07-01.)
ArticleCitations
Editorial Expression of Concern: Targeting microRNAs as a promising anti-cancer therapeutic strategy against traffic-related air pollution-mediated lung cancer187
Immunotherapy for leptomeningeal disease from solid tumors: current clinical outcomes and future opportunities179
Regulation of dormancy during tumor dissemination: the role of the ECM140
The impact of tumor microenvironment: unraveling the role of physical cues in breast cancer progression100
The functions and modifications of tRNA-derived small RNAs in cancer biology80
Clonal tracking in cancer and metastasis76
Of vascular defense, hemostasis, cancer, and platelet biology: an evolutionary perspective71
New insights for gynecological cancer therapies: from molecular mechanisms and clinical evidence to future directions64
CAR T-cell therapy for B-cell lymphomas: outcomes and resistance mechanisms59
The role of microbiome in pancreatic cancer55
Obesity and cancer48
Progression and metastasis of small cell lung carcinoma: the role of the PI3K/Akt/mTOR pathway and metabolic alterations47
The paradoxical role of inositol in cancer: a consequence of the metabolic state of a tumor47
CAR T-cell therapy to treat multiple myeloma: current state and future directions47
Targeting lipid metabolism in cancer: neuroblastoma47
Immunotherapy for triple negative breast cancer: the end of the beginning or the beginning of the end?47
The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer47
Cell-cell interactions mediating primary and metastatic breast cancer dormancy46
TRIM-endous functional network of tripartite motif 29 (TRIM29) in cancer progression and beyond43
p73 isoforms meet evolution of metastasis40
KISS1 metastasis suppressor in tumor dormancy: a potential therapeutic target for metastatic cancers?39
Natural killer cells in neuroblastoma: immunological insights and therapeutic perspectives39
A multidisciplinary perspective on the complex interactions between sleep, circadian, and metabolic disruption in cancer patients38
Preface37
Healthcare disparities, screening, and molecular testing in the changing landscape of non–small cell lung cancer in the United States: a review37
Targeting microRNAs as a promising anti-cancer therapeutic strategy against traffic-related air pollution-mediated lung cancer36
Biography—Mathieu Boissan, Pharm.D., Ph.D36
LGR5: An emerging therapeutic target for cancer metastasis and chemotherapy resistance35
Neuropeptide Y in cancer—biological functions and potential clinical implications33
Biographies32
Biographies31
The multifaceted mechanisms of malignant glioblastoma progression and clinical implications30
The role of cancer cell bioenergetics in dormancy and drug resistance30
Targeting DNA damage repair pathways in pancreas cancer30
Short-chain fatty acids in cancer pathogenesis29
Cross-talk between the microbiome and chronic inflammation in esophageal cancer: potential driver of oncogenesis28
Immunomodulatory role of oncogenic alterations in non-small cell lung cancer: a review of implications for immunotherapy28
How circulating tumor cluster biology contributes to the metastatic cascade: from invasion to dissemination and dormancy28
Role of Neuropilin-2-mediated signaling axis in cancer progression and therapy resistance28
Systematic review of the receptor tyrosine kinase superfamily in neuroblastoma pathophysiology27
Clusterin: a marker and mediator of chemoresistance in colorectal cancer27
Helicobacter pylori–activated fibroblasts as a silent partner in gastric cancer development26
Tumor necrosis factor superfamily signaling: life and death in cancer25
Clinical interventions to break the obesity and cancer link: a narrative review24
Tissue-engineered patient-derived osteosarcoma models dissecting tumour-bone interactions24
The tumor microenvironment in pancreatic ductal adenocarcinoma: current perspectives and future directions24
Vaping and tumor metastasis: current insights and progress23
The emerging roles of histone demethylases in cancers23
Epigenetic reprogramming of T cells: unlocking new avenues for cancer immunotherapy22
Carcinoma of unknown primary (CUP): an update for histopathologists22
Impact of posttranslational modifications in pancreatic carcinogenesis and treatments22
Dormancy, stemness, and therapy resistance: interconnected players in cancer evolution21
Heterogeneity and tumor evolution reflected in liquid biopsy in metastatic breast cancer patients: a review21
Kenneth V. Honn, Ph.D. (1946–2023)21
Debris-stimulated tumor growth: a Pandora’s box?21
Functional and clinical roles of stromal PDGF receptors in tumor biology21
Inflammatory bowel disease and carcinogenesis20
The role of mitochondria in tumor metastasis and advances in mitochondria-targeted cancer therapy20
HOXA9 transcription factor is a double-edged sword: from development to cancer progression20
Racial disparity in prostate cancer: an outlook in genetic and molecular landscape20
New progress of tuberculosis scar carcinoma20
OX40/OX40 ligand and its role in precision immune oncology20
The strict regulation of HIF-1α by non-coding RNAs: new insight towards proliferation, metastasis, and therapeutic resistance strategies19
Oncogenic functions of the FOXC2 transcription factor: a hallmarks of cancer perspective19
CTGF (CCN2): a multifaceted mediator in breast cancer progression and therapeutic targeting19
The plasticity of pancreatic cancer stem cells: implications in therapeutic resistance19
PRUNE1 and NME/NDPK family proteins influence energy metabolism and signaling in cancer metastases19
UCP2 and pancreatic cancer: conscious uncoupling for therapeutic effect19
Ferroptosis: iron release mechanisms in the bioenergetic process18
Multifaceted role of the DNA replication protein MCM10 in maintaining genome stability and its implication in human diseases18
0.042523860931396